Search PubMed⌕ Search

Biomedical subjects

J D Cash

Publications and source records attributed to J D Cash.

At least 37 records · Page 2Linked to original sources
PubMed1981

A clinical trial on the early detection and correction of haemostatic defects in selected high-risk neonates.

Low birth weight infants, preterm infants with respiratory distress syndrome and mature infants with asphyxia were screened for coagulation abnormalities as soon as possible after birth. Those with abnormal haemostasis were assigned to control or treatment groups and, in the latter case, were given prothrombin complex concentrate, cryoprecipitate or platelet concentrate as appropriate. This treatment was largely successful in correcting haemostatic defects but did not result in any change in mortality. There was no evidence of adverse or beneficial side-effects of treatment.

Asphyxia Neonatorum↗
PubMed1981

The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland.

During the last 9 years, two factor IX concentrates produced in Scotland, PPSB and DEFIX, have been used for the treatment of haemophilia B and acquired coagulation disorders, including those due to liver disease, coumarin therapy, neonatal immaturity and post-operative bleeding. During the period of study 112 batches of DEFIX and 40 batches of PPSB were used in the Edinburgh and South-East Scotland Region. Data were analysed from 575 non-haemophilic patients, receiving 968 treatment episodes, as well as 24 haemophiliacs. Serial coagulation studies and analysis of retrospective data showed that both concentrates corrected the coagulation deficiencies in all the above patient groups; in no case was there any evidence of intravascular coagulation resulting from concentrate infusion.

Blood Coagulation Disorders↗
PubMed1980

Clinical use of a human albuminoid preparation (SPPS) produced by the continuous small volume mixing (CSVM) fractionation technique.

Since the commissioning of the Scottish National Blood Transfusion Service's Protein Fractionation Centre in 1975 840 batches (in excess of 150,000 bottles) of stable purified protein solution (SPPS), prepared by the continuous small volume mixing (CSVM) method, have been used clinically. Each bottle contains approximately 400 ml of a solution of 4.3 g% total protein of which greater than 85% is albumin (mean 89%). Prekallikrein activator (PKA) estimations on the last 120 batches have revealed a mean value 8.0% +/- 6.1 with reference to the U.S.A. (B.O.B.) Reference Standard (Ref. 1). Using gel filtration techniques and UV Absorption at 280 nm approximately 7% of the albumin is in polymer form. It has been calculated that there have been in excess of 40,000 separate patient exposures. SPPS has been used in the cardiac bypass situation and in large volume plasma exchange using cell separators. Clinical colleagues consider its clinical efficacy in the management of hypovolaemic patients to be of a high order. The issue of SPPS for clinical purposes is controlled by the Regional Transfusion Centres either directly or through their peripheral blood banks. Because there is close and active liaison in the reporting of adverse reactions to routine blood transfusion, similar conditions apply to all plasma products, including SPPS. In the period under retrospective review adverse reactions to isolated bottles in two batches (3 patients) of SPPS have been reported (an incidence of 0.24% batches produced). None of these reactions was fatal and none was explained. It is concluded that the SPPS produced by our Protein Fractionation Centre, using the CSVM technique, appears to have a satisfactory record with regard to efficacy and safety.

Adult↗
PubMed1979

Specificity in the factor VIII response to vasopressin infusion in man.

Structural requirements of the systemic factor VIII response to intravenous vasopressin in man has been investigated using vasopressin analogues. With the analogues available the receptor specificity of this phenomenon could not be distinguished from those associated with the previously described plasminogen activator release or antidiuretic effects of this hormone. Further studies using 1-desamino-[8-D-arginine]vasopressin showed a dose-related release of both procoagulant and antigenic components of the factor VIII complex. The newly released factor VIII could not be distinguished from circulating factor VIII on the basis of molecular size, electrophoretic mobility or in vitro stability despite apparent differences in the duration of response of the procoagulant and antigenic components in vivo.

Adult↗
PubMed1979

Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis.

In eight patients with cirrhosis of the liver and portal hypertension an intravenous infusion of lysine vasopressin induced a rapid increase in the plasma level of the fibrinolytic proenzyme plasminogen activator. In contrast, triglycyl lysine vasopressin (glypressin; GVP), in a dose known to lower portal venous pressure, produced no fibrinolytic response. This lack of fibrinolytic response represents an advantage of GVP over lysine vasopressin in addition to its longer in vivo half-life and lower cardiotoxicity. Clinical trials of GVP in the treatment of bleeding oesophageal varices are needed.

Aged↗
PubMed1978

beta-thromboglobulin and deep vein thrombosis.

The measurement of plasma beta-thromboglobulin as a potential diagnostic test for venous thrombosis has been investigated in 16 normal volunteers, 24 patients presenting with deep vein thrombosis (DVT) or pulmonary embolism and 46 patients screened by 125I fibrinogen test (IFT) for post-operative DVT. The normal mean was 33 ng/ml (range 15-117 ng/ml). Of the 24 patients with clinical thrombotic disease 22 presented with DVT confirmed by phlebogram or IFT and 2 presented with embolism confirmed by lung scan. At the time of first presentation 12 out of 24 had betaTG values greater than 70 ng/ml. All except 3 of this group of 24 patients had values of greater than 70 ng/ml at some stage during a subsequent week of daily sampling. DVT was detected in 13 out of 46 screened post-operative patients. There was a rise om betaTG observed within 24 hr of the IFT becoming positive but the mean rise did not reach significance at the 5% level. An association between DVT and high betaTG values has been confirmed. However, its clinical value cannot yet be fully elucidated until factors, probably related to blood sampling and clearance, are further investigated.

Beta-Globulins↗
PubMed1977

The different forms of antithrombin II in serum.

Antithrombin III (AT III) complexes were isolated from human serum by affinity chromatography and gel filtration. In the first step of the preparation, using heparin-agarose chromatography, we observed that the complexed form of AT III bound less strongly to the gel than the free form and that about half of the AT III was free. With further purification a 2.5 X 10(5) molecular weight complex was isolated. Using 125I labelled human thrombin, this complex was radioactive indicating the presence of thrombin. Only in a synthetic thrombin-AT III system was a 9 X 10(4) molecular weight complex detected, but not in serum. These facts suggest that in serum AT III complexes may exist in a polymeric form. Also, an AT III antigen derived from the original AT III molecule, but not complexed, was isolated which may be a degradation product.

Antigens↗